Showing 5411-5420 of 8820 results for "".
- FDA Agrees to Priority Review of Cemiplimab for Advanced Squamous Cell Carcinomahttps://practicaldermatology.com/news/fda-agrees-to-priority-review-of-cemiplimab-for-advanced-squamous-cell-carcinoma/2457785/The FDA has accepted the Biologics License Application (BLA) for cemiplimab for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or patients with locally advanced CSCC w
- New Phase 4 Data: Epiduo Forte Gel Decreased Acne Lesions, Reduced Risk of Scarshttps://practicaldermatology.com/news/new-phase-4-data-epiduo-forte-gel-decreased-acne-lesions-reduced-risk-of-scars/2457788/Results from OSCAR, a Phase 4, multicenter, randomized, investigator-blinded, vehicle-controlled, intra-individual comparison study (right/left half-face), revealed that Epiduo Forte (adapalene and benzoyl peroxide) Gel 0.3%/2.5% not only decreased acne lesions, as measured over a period of
- Acne Survey at Twins Convention Affirms Genetic Linkhttps://practicaldermatology.com/news/acne-survey-at-twins-convention-affirms-genetic-link/2457789/A survey of identical and fraternal twin pairs at the Twins Days Festival in Twinsburg, OH, and published in the April issue of the Journal of Drugs in Dermatology, shows acne may be primarily caused by genetics.
- Melanoma Reduces Alzheimer's Risk: Studyhttps://practicaldermatology.com/news/melanoma-reduces-alzheimers-risk-study/2457794/Individuals diagnosed with malignant melanoma may have a reduced risk of developing Alzheimer's disease. New findings, recently published online in
- First Androgenetic Alopecia Patient Dosed in a Pilot Study with Aclaris' ATI-502 Topicalhttps://practicaldermatology.com/news/first-androgenetic-alopecia-patient-dosed-in-a-pilot-study-with-aclaris-ati-502-topical/2457795/Aclaris Therapeutics, Inc. initiated a Phase 2 open-label study of ATI-502, a topical Janus Kinase (JAK) 1/3 inhibitor (ATI-502 Topical), in patients with androgenetic alopecia (AGA), a condition characterized by a genetically determined male/female-pattern baldness. This trial will
- AAD Awards 26 Shade Structure Grants to Protect America's Youthhttps://practicaldermatology.com/news/aad-awards-26-shade-structure-grants-to-protect-americas-youth/2457796/The American Academy of Dermatology (AAD) has awarded Shade Structure grants to 26 schools and nonprofit organizations across the country. The AAD awarded its 2018 AAD Shade Structure grants to the following organizations: Alabama
- Physician Assistant Groups Respond to JAMA Dermatology Study: "Fundamentally Flawed"https://practicaldermatology.com/news/physician-assistant-groups-respond-to-jama-dermatology-study-fundamentally-flawed/2457798/The American Academy of PAs (AAPA) and the Society of Dermatology PAs (SDPA) have issued a statemen
- Saudi Arabia Welcomes Scalisi Skin Carehttps://practicaldermatology.com/news/saudi-arabia-welcomes-scalisi-skin-care/2457799/Select doctors’ offices and medical clinics across Saudi Arabia now carry the Scalisi collection. This adds to their existing distribution in spas and medispas in the US, Wynn and Encore Resorts in both Las Vegas, and Macau, China, and online on QVC.com, Amazon.com, and
- Most Indoor Tanners Aren't Getting Screened for Skin Cancerhttps://practicaldermatology.com/news/most-indoor-tanners-arent-getting-screened-for-skin-cancer/2457801/Most indoor tanners are not getting checked for skin cancer, a new study shows. Researchers analyzed data from the National Health Interview Survey of more than 30,000 U.S. adults. They looked at rates of s
- Using Anti-PD-1 Therapy Pre-Surgery in Melanoma Patients Can Identify Those Most Likely to Benefithttps://practicaldermatology.com/news/using-anti-pd-1-therapy-pre-surgery-in-melanoma-patients-can-identify-those-most-likely-to-benefit/2457806/Shifting use of anti-PD-1 drugs to before surgery may provide clues about which patients will benefit and which may be at increased risk for recurrence, according to new research out of the Abramson Cancer Center of the University of Pennsylvania.